Scroll to Section

Scroll to a section with a highlight animation to draw attention. Uses a useScrollToSection hook and a ScrollHighlight wrapper.

Live Demo

Click any section button in the navigation bar below. The page scrolls to that section and a ring + glow animation highlights it for 1.5 seconds.

Jump to Section

Click a section to scroll and highlight it

Executive Summary

Q3 2026 Drug Discovery Pipeline Report

This report summarizes the progress of our lead compound RG-7842 through Phase II clinical trials. Key findings indicate a statistically significant improvement in primary endpoints compared to the standard of care, with a manageable safety profile.

87%

Response Rate

p<0.001

Significance

342

Patients Enrolled

Assay Results

In-vitro and in-vivo assay outcomes

IC50 Binding Assay

12.4 nMPass

Cell Viability (MTT)

94.2%Pass

hERG Channel Inhibition

< 10%Pass

CYP3A4 Inhibition

23.1%Review

Plasma Protein Binding

89.7%Pass

Statistical Analysis

Primary and secondary endpoint analysis

Endpoint

Treatment

Control

p-value

Overall Response Rate

87.2%

54.1%

< 0.001

Progression-Free Survival

18.3 mo

11.7 mo

0.003

Duration of Response

14.8 mo

9.2 mo

0.012

Complete Response

31.4%

12.8%

< 0.001

Risk Assessment

Identified risks and mitigation strategies

CYP3A4 drug-drug interaction potentialMedium

Mitigation: Dose adjustment protocol for concomitant CYP3A4 inhibitors

Grade 3+ neutropenia in 8.2% of patientsMedium

Mitigation: Prophylactic G-CSF recommended for high-risk patients

Limited data in hepatic impairmentLow

Mitigation: Dedicated PK study planned for Phase III

Conclusions

Summary of findings and next steps

RG-7842 demonstrates superior efficacy vs. standard of care across all primary endpoints

Safety profile is manageable with established mitigation strategies

Recommend advancement to Phase III with expanded enrollment criteria

Biomarker-driven patient selection may further improve response rates

Report generated on July 13, 2026. Data cutoff: June 30, 2026. All analyses performed per pre-specified statistical analysis plan (SAP v2.1).

Usage

1. Import the hook

import { useScrollToSection } from "@/lib/use-scroll-to-section";
import { ScrollHighlight } from "@/components/ui/scroll-highlight";

2. Register sections and scroll

const { registerRef, scrollTo, highlightedId } = useScrollToSection();

// Wrap each target section
<ScrollHighlight
  ref={registerRef("claims")}
  highlighted={highlightedId === "claims"}
>
  <Card>...</Card>
</ScrollHighlight>

// Trigger scroll from anywhere
<Button onClick={() => scrollTo("claims")}>
  Go to Claims
</Button>

Options

Hook options

useScrollToSection({
  offset: 80,            // px from top (default: 80)
  behavior: "smooth",    // scroll behavior (default: "smooth")
  highlightDuration: 1500 // ms (default: 1500)
})

Highlight animation

The highlight uses a ring-2 ring-primary/60 border with a highlight-pulse keyframe that fades a glow shadow from visible to transparent over 1.5s.

Components Used

useScrollToSection

Hook — scroll + highlight state

ScrollHighlight

Wrapper — ring + glow animation

@cs-coe/card

Section containers

@cs-coe/button

Navigation triggers

@cs-coe/badge

Status indicators